Name of the Issue: Akums Drugs and Pharmaceuticals Limited

1	**Type of Issue**	Initial Public Offer
2	**Fresh Issue Size (INR mn)**	6,800.0
	Offer for Sale (INR mn)	11,767.4

Source: Prospectus dated August 1, 2024

3 Grade of issue along with name of the rating agency

Name	NA
Grade	NA

4	**Subscription Level (Number of times)[1]**	63.66x

Source: Basis of allotment dated August 2, 2024

Note: (1) Prior to rejections

5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%age
(i) Allotment in the Issue[1]	12.93%
(ii) at the end of 1st Quarter immediately after the listing (September 30, 2024)	14.86%
(iii) at the end of 1st FY (March 31, 2025)	13.17%
(iii) at the end of 1st FY (March 31, 2026)	15.72%
(iv) at the end of 2nd FY (March 31, 2027)[1]	NA

Source: Regulatory Filings with the stock exchange

Note: (1) Will be updated in due course

6 Financials of the Issuer

(INR mn)

Parameters	1st FY (March 31, 2025)	2nd FY (March 31, 2026)	3rd FY (March 31, 2027)[1]
Revenue from operations	41,182	43,590	N.A.
Net Profit	3,438	2,564	N.A.
Paid up Equity Share Capital	306	306	N.A.
Reserves excluding revaluation reserves[2]	30,164	32,827	N.A.

Note: (1) Will be updated in due course, (2) Other Equity

7 Trading Status

Company's Equity Shares are listed on both the BSE Limited and the NSE.The Shares have not been suspended or delisted.

Particulars	Status
(i) Current Status	Active
(ii) at the end of 1st FY (March 31, 2025)	Active
(ii) at the end of 2nd FY (March 31, 2026)	Active
(iii) at the end of 3rd FY (March 31, 2027)(1)	N.A.

Note: (1) Will be updated in due course

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2025)	Nand Lal Kalra	Resigned
(ii) at the end of 2nd FY (March 31, 2026)	Anil Kumar Arvindlal Amin	Appointed
(iii) at the end of 3rd FY (March 31, 2027)(1)	N.A.	N.A.

Note: (1) Will be updated in due course

9 Status of implementation of project/ commencement of commercial production

(i) As disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

Particulars	Total estimated Fund requirement
(i) As disclosed in the offer document (Net Proceeds)(1)	6,421.80
(ii) Actual utilization (INR mn)(2)	6,373.70
(iii) Reasons for deviation, if any	Not applicable

Note: (1) During the quarter ended March 31, 2026, unutilised issue expenses of Rs 48.10 million has been reallocated towards the object of - "GCP" by Rs 25 million & "Pursuing inorganic growth initiatives through acquisitions" by Rs 23.10 million as actual utilization towards issue expenses is lower than the proposed deployment resulting in an increase in net proceeds. The amount utilised for general corporate purposes does not exceed 25% of the Gross Proceeds (amounting to Rs 1700.00 million). The reallocation of proceeds was duly approved by the Board of Directors of the Company through a resolution dated 13th February 2026. (2) Utilized upto March 31, 2026

11 Comments of monitoring agency, if applicable

(a) Comments on use of funds	Not applicable
(b) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	No deviation observed
(c) Any other reservations expressed by the monitoring agency about the end use of funds	Not applicable

Source: Monitoring agency report for the quarter ended March 31, 2026

12 Pricing Data

Issue Price (Rs.) 679

Designated Stock Exchange: NSE

Listing Date: 06-Aug-24

Price parameters	At close of listing day (August 6, 2024)	Close of 30th calendar day from listing day (September 4, 2024)	Close of 90th calendar day from listing day (November 1, 2024)	At the end of FY 2025[1]			At the end of FY 2026[1]			At the end of FY 2027[1,2]		
				Closing price	High	Low	Closing price	High	Low	Closing price	High	Low
Market Price (NSE)	796.3	897.0	855.7	473.2	1,175.9	432.6	466.1	623.0	405.0	NA	NA	NA
Nifty 50	23,992.6	25,198.7	24,304.4	23,519.4	26,277.4	21,281.5	22,331.4	26,373.2	21,743.7	NA	NA	NA

Note: (1) High / Low denotes intraday High / Low for the entire period.
(2) Will be updated in due course.

Source: NSE website

13 Basis for Issue Price

Accounting ratio	Name of Company	As disclosed in the offer document	At the end of 1st FY (FY 2025)[1]	At the end of 2nd FY (FY 2026)	At the end of 3rd FY (FY 2027) [7]
EPS (Diluted)(Rs.)	**Issuer:**	-0.28	22.60	16.67	N.A.
	Peers Average	49.79	57.13	64.53	N.A.
	Divi's Laboratories	60.27	82.53	96.75	N.A.
	Suven Pharma	11.80	12.68	4.68	N.A.
	Gland Pharma	46.89	42.40	62.28	N.A.
	Torrent Pharma	48.94	56.47	63.92	N.A.
	Alkem Laboratories	150.19	181.11	192.51	N.A.
	Eris Lifesciences	28.79	25.81	45.26	N.A.
	JB Chemicals	34.85	41.56	44.45	N.A.
	Mankind Pharma	47.68	49.20	46.28	N.A.
	Innova Captab	18.66	22.41	24.63	N.A.

P/E[2]	**Issuer:**	N.A.[3][4]	21.00	27.96	NA
	Peers Average	49.14	51.65	43.68	N.A.
	Divi's Laboratories	74.99	69.95	61.47	N.A.
	Suven Pharma	69.54	90.77	64.41	N.A.
	Gland Pharma	42.45	37.55	27.23	N.A.
	Torrent Pharma	60.20	57.28	66.02	N.A.
	Alkem Laboratories	34.18	26.95	27.53	N.A.
	Eris Lifesciences	34.95	54.88	28.66	N.A.
	JB Chemicals	51.38	39.03	46.44	N.A.
	Mankind Pharma	44.65	49.25	43.34	N.A.
	Innova Captab	29.91	39.16	28.01	N.A.
NAV per Equity Share[5]	**Issuer:**	49.59	192.96	210.51	NA
	Peers Average	327.10	385.65	432.01	N.A.
	Divi's Laboratories	511.21	563.87	631.37	N.A.
	Suven Pharma	80.56	148.99	99.68	N.A.
	Gland Pharma	529.65	555.41	628.68	N.A.
	Torrent Pharma	202.57	224.29	247.87	N.A.
	Alkem Laboratories	862.46	1002.37	1155.87	N.A.
	Eris Lifesciences	190.12	240.28	280.95	N.A.
	JB Chemicals	188.37	220.54	259.05	N.A.
	Mankind Pharma	233.73	347.39	394.03	N.A.
	Innova Captab	145.20	167.66	190.61	N.A.
RoNW (%)[6]	**Issuer:**	-0.57%	11.14%	7.70%	NA
	Peers Average	15.85%	15.07%	14.43%	N.A.
	Divi's Laboratories	11.79%	14.64%	15.32%	N.A.
	Suven Pharma	14.64%	12.85%	4.58%	N.A.
	Gland Pharma	8.85%	7.63%	9.92%	N.A.
	Torrent Pharma	24.15%	25.17%	25.78%	N.A.
	Alkem Laboratories	17.41%	18.07%	16.66%	N.A.
	Eris Lifesciences	15.16%	10.75%	15.87%	N.A.
	JB Chemicals	18.90%	19.21%	17.06%	N.A.
	Mankind Pharma	20.43%	13.89%	11.74%	N.A.
	Innova Captab	11.35%	13.37%	12.92%	N.A.

Sourced from Prospectus dated August 1, 2024

Note: (1) Last working day for the the FY2025 is on 28th March and for FY26 is on 30th March (2) P/E based on diluted EPS; Price as on 31st March (3) At Offer Price (4) Diluted EPS is Negative per the offer document (5) NAV is defined as Net Worth at the year end divided by Outstanding Equity Shares at the year end (6) RoNW is defined as Net Profit/(Loss) After Tax at the year end as a % of Net Worth at the year end (7) Will be updated in due course

14 Any other material information

Particulars	Date	Remarks
Shares of Akums Drugs and Pharmaceuticals Limited got listed on BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”)	06-Aug-24	-
Mr. Amrut Medhekar has been appointed as Chief Executive Officer - CDMO Business	24-Aug-24	-
Akums has entered into a License and Distribution Agreement with Triple Hair Inc, Canada for exclusive rights to further develop and market the products recently innovated by Triple Hair Inc, in the Territory of India after obtaining the necessary regulatory approvals and licenses in India	16-Oct-24	-
Akums has executed a Memorandum of Undertaking with the Government of Republic of Zambia on local manufacturing of medicines	18-Oct-24	-
Akums has entered into an exclusive Master Sales Agreement with Caregen Co., Ltd, South Korea in Nutraceuticals segment	19-Nov-24	-
Maxcure, a wholly owned subsidiary of Akums, has entered into a collaboration agreement with Jagdale Industries exclusively focusing on aseptic manufacturing and subsequent filling in carton packing or the Ready to Drink market	26-Nov-24	-
Akums has entered into an agreement with one of the leading global pharma company for manufacturing and supply of selected pharmaceutical formulations in European market.	24-Dec-24	-
Mr. Nand Lal Kalra has ceased to be an Independent Director of the company w.e.f. 05.02.2025 due to attaining the age of 75 years	05-Feb-25	-
Akums was awarded a patent for Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation, designed for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, valid for a term of 20 years	14-Feb-25	-
Mr. Ashish Sharma, Vice President- ESG & Sustainability, designated as Senior Management Personnel of the Company, has resigned from his position to explore new professional opportunities	26-Mar-25	-
Mr. Amrut Medhekar has resigned from his position of Chief Executive Officer - CDMO Business w.e.f. 15-Jul-2025	26-May-25	-
The Board of Directors approved the appointment of Mr. Anil Kumar Arvindlal Amin as an additional director (Non-Executive-Independent) of the company w.e.f June 04, 2025 for a term of five consecutive years	04-Jun-25	-
Mr. Jitendra Mishra, Sr. Vice-President- IT, designated as Senior Management Personnel of the Company has resigned from his position.	05-Jul-25	-
Release of Q1 FY26 Results	04-Aug-25	-
Executed a Framework Agreement with Government of the Republic of Zambia to establish a local manufacturing facility in Zambia and to undertake the manufacturing and supply of Medicines in Zambia, with the objective of supporting GRZ national health programs and enhancing local production capabilities in Zambia. This Project shall be implemented through incorporation of a new joint venture company in Zambia in which Akums will be a majority partner owning 51% stake and a nominated Zambian state instrumentality owning 49% stake.	22-Aug-25	-
Mr. Sanjay Sharma, President - Portfolio & Strategy, designated as Senior Management Personnel of the Company has resigned from his position.	10-Oct-25	-
Incoporated a Joint Venture Company in Zambia in the name and style of Akums Healthcare (Zambia) Private Limited	13-Oct-25	-
Incorporated a Wholly Owned Subsidiary of the Company Malta, Europe in the name and style of “Akums Healthcare Malta Private Limited”	20-Oct-25	-

Received patent for “Dual Release Gastro-Resistant Composition” for the term of 20 years	03-Nov-25	-
Release of Q2 FY26 Results	08-Nov-25	-
BoD approved: Dr. Shantanu Rajaram Chobhe – President (CQA) Formulation, as Senior Management Personnel w.e.f 13.11.2025 Mr. Vinayak Bhat – VP (Operations) API division, as Senior Management Personnel w.e.f 13.11.2025.	13-Nov-25	-
BoD approved investment of USD 24 million (INR 200 Crores approx.) in Akums Healthcare (Zambia) Private Limited, a subsidiary incorporated in the Republic of Zambia. The proposed investment will be in the form of equity and / or debt (secured by MIGA insurance), and be infused in a staggered manner. The purpose of this investment is to set up a manufacturing facility and to expand its business operations in the Zambian market and meet the growing demand in neighbouring African countries.	13-Nov-25	-
Ruby QC Investments Pte Ltd disposed 4.62% (% w.r.t. total diluted share / voting capital of the TC) equity shares of Akums Drugs and Pharmaceuticals Limited through a Block Deal	22-Dec-25	-
Mr. Rajkumar Bafna, President – Finance, designated as Senior Management Personnel of the Company has resigned from his position with effect from 31st December, 2025	27-Dec-25	-
Akums Drugs and Pharmaceuticals Limited has received European GMP certificates for its two facilities, Plant 1 and Plant 2, both located at Haridwar, Uttarakhand. While the certification for Plant 1 represents a renewal of its existing EU-GMP approval, Plant 2 has received EU-GMP certification for the first time.	23-Jan-26	-
Release of Q3 FY26 Results and Monitoring Agency Report	13-Feb-26	-
Release of reaffirmed/new credit rating report, issued by ICRA Limited	11-Apr-26	-
Pure and Cure Healthcare Private Limited, a wholly-owned subsidiary of the Company, has executed a lease deed for purchasing an industrial plot in Haridwar of app. 4050 sq.m.	29-Apr-26	-
Release of Q4 FY26 and FY26 Results	14-May-26	-
The Board of Directors have recommended a final dividend of Rs. 1.00/- (@ 50%) per equity share and a special dividend of Rs. 2.00/- (@ 100%) per equity share having face value of Rs. 2/- (Rupees Two) each fully paid-up for the Financial Year ended March 31, 2026, subject to the approval of the Shareholders of the Company at the ensuing AGM	14-May-26	-
Re-appointment of M/s. Balwinder & Associates, Cost Accountants as Cost Auditors of the Company for the F.Y. 2026-27	14-May-26	-
Appointment of Mahajan & Aibara LLP, Chartered Accountants as Internal Auditors of the Company for the F.Y. 2026-27	14-May-26	-
Appointment of Mr. V Jagannathan, President – HR as Senior Management Personnel of the Company.	14-May-26	-
Cessation of Mr. Arvind Srivastava, President – HR as Senior Management Personnel of the Company	14-May-26	-
Release of Q4 FY26 Monitoring Agency Report	14-May-26	-

Company informed that the partially disrupted manufacturing operations across various sites in Haridwar have been successfully resumed at 100% operational capacity with effect from 18th May, 2026. The partial disruption in production lasted for four days, resulting in delayed supply of approx. INR 200mn.	18-May-26	-
Receipt of Assessment Order from Income Tax Department of ~INR600mn on account of disallowance of various expenditures. Based on internal assessment, the Company does not expect the said order to have any material financial impact citing them as unsustainable in the law and defendable basis the facts of the case.	20-May-26	-
Receipt of Assessment Order by Maxcure Nutravedics Ltd., Pure and Cure Healthcare Pvt. Ltd., Malik Lifesciences Pvt. Ltd. And Nicholas Healthcare Ltd. from Income Tax Department on account of disallowance of various expenditures.	22-May-26	-